Propranolol for Infantile Hemangiomas


Por: Bagazgoitia, L, Torrelo, A, Gutierrez, JCL, Hernandez-Martin, A, Luna, P, Gutierrez, M, Bano, A, Tamariz, A, Larralde, M, Alvarez, R, Pardo, N, Baselga, E

Publicada: 1 mar 2011
Resumen:
Propranolol has been used successfully in a limited number of children with infantile hemangiomas. This multicenter retrospective study describes the efficacy and adverse effects of propranolol in infantile hemangioma. Seventy-one infants with infantile hemangiomas were treated with oral propranolol, 1 mg/kg/12 hours, for at least 12 weeks. A photograph based severity scoring assessment was performed by five observers to evaluate efficacy, utilizing a scoring system of 10 as the original infantile hemangioma before treatment and 0 as completely normal skin. The mean of the five independent measurements was used in the analysis. Propranolol was a rapid and effective treatment for infantile hemangiomas at 4 weeks (p < 0.001), at 8 weeks (p < 0.001 compared to the 4 wks value), at 12 weeks (p < 0.05 compared to the 8 wks value), and thereafter up to 32 weeks (p < 0.01 compared to the 16 wks value). The response of infantile hemangiomas to propranolol was similar regardless of sex, age at onset of treatment, type of involvement (segmental and nonsegmental), facial segments affected, special locations (eyelid, nasal tip, and parotid region), ulceration, and depth of infantile hemangiomas. Very few side effects were reported; mainly agitated sleep in 10 of 71 patients. In the series of patients in this study, oral propranolol 2 mg/kg/day was a well-tolerated and effective treatment for infantile hemangiomas. Prospective studies are needed to establish the exact role of propranolol in the treatment of infantile hemangiomas.

Filiaciones:
Bagazgoitia, L:
 Hosp Ninus Jesus, Dept Dermatol, Madrid 28009, Spain

Torrelo, A:
 Hosp Ninus Jesus, Dept Dermatol, Madrid 28009, Spain

Gutierrez, JCL:
 Hosp La Paz, Dept Pediat Surg, Madrid, Spain

Hernandez-Martin, A:
 Hosp Ninus Jesus, Dept Dermatol, Madrid 28009, Spain

Luna, P:
 Hosp Ramos Mejia, Dept Dermatol, Buenos Aires, DF, Argentina

Gutierrez, M:
 Hosp Ninus Jesus, Dept Dermatol, Madrid 28009, Spain

Bano, A:
 Hosp Ninus Jesus, Dept Pediat Cardiol, Madrid 28009, Spain

Tamariz, A:
 Hosp Ninus Jesus, Dept Pediat Cardiol, Madrid 28009, Spain

Larralde, M:
 Hosp Ramos Mejia, Dept Dermatol, Buenos Aires, DF, Argentina

 Hosp Aleman, Dept Dermatol, Buenos Aires, DF, Argentina

Alvarez, R:
 Hosp Santa Creu & Sant Pau, Dept Pediat Cardiol, Barcelona, Spain

Pardo, N:
 Hosp Santa Creu & Sant Pau, Dept Pediat, Barcelona, Spain

Baselga, E:
 Hosp Santa Creu & Sant Pau, Dept Dermatol, Vasc Unit, Barcelona, Spain
ISSN: 07368046





PEDIATRIC DERMATOLOGY
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 28 Número: 2
Páginas: 108-114
WOS Id: 000290381900004
ID de PubMed: 21385205

MÉTRICAS